Datamonitor, Sep 2010
Introduction
This model contains a 10 year country, indication, and device specific forecasts for individual products used in asthma and COPD, taking into account competitive positioning and key
Business Insights, May 2011, Pages: 81
in the respiratory market over the period 2010–16.
Highlights
The global respiratory market was valued at $44.0bn in sales in 2010 with asthma/COPD drugs being the key revenue drivers of the therapeutic segment
IMS Health, Jan 2007, Pages: 293
, Japan, Mexico, Spain, the UK and the USA. We then conclude the report with a highly inclusive analysis of the markets future growth potential. Executive Summary
Anti asthma/ COPD Products Key
Frost & Sullivan, April 2011, Pages: 114
This research service provides an in depth analysis of factors affecting the growth of the U.S. asthma/COPD market over the period 2006-2016. Included is a disease overview, product analysis, total
GBI Research, Nov 2011, Pages: 76
GBI Research’s report, “Clinical Trial Recruitment in Respiratory Diseases - Most Clinical Trial Activity Focused on Asthma and COPD”, provides an in-depth analysis of patient recruitment scenario
Elsevier Science and Technology, Nov 2008, Pages: 896
The Second Edition of Asthma and COPD: Basic Mechanisms and Clinical Management continues to provide a unique and authoritative comparison of asthma and COPD. Written and edited by the world
Datamonitor, June 2009
.
Key reasons to purchase this title
- Identify key opportunities and threats that will impact the use and uptake of new and existing products
- Quantify the future size and scope of the asthma/COPD
Datamonitor, Oct 2011, Pages: 157
Despite a number of well-established therapies, the asthma/COPD pipeline remains highly active. A number of products have progressed in the pipeline and significant new data have been presented
Espicom Business Intelligence Ltd, Aug 2006, Pages: 96
that this could increase to 400-450 million by 2025. Around 30 million people in Europe have asthma, six million of whom have severe symptoms and around 1.5 million live in fear of dying from an attack.
COPD
Datamonitor, Sep 2010, Pages: 115
Datamonitor estimates that in 2009 asthma/COPD sales reached $21.5 billion in the seven major markets. The next 10 years will see the dynamic pipeline fracture a market currently dominated
Business Insights, Jan 2005
In terms of revenue, the asthma and COPD therapeutic area historically ranks as the sixth largest single source of sales for the pharmaceutical industry. The outlook for the market is currently
John Wiley and Sons Ltd, April 2008, Pages: 326
constriction in Asthma and COPD
- Relates latest research to bronchodilator therapy
- Multi-contributed text, co-coordinated by two of the leading authorities in the field. Airway Smooth Muscle in Asthma
Informa Healthcare, Aug 2006, Pages: 233
the mechanisms that regulate the development of bronchial vascular remodeling in asthma and COPD, as well as explore the pathophysiological processes that may impact the formulation of new therapeutic strategies
VDM Publishing House, Sep 2008, Pages: 76
for discriminative purposes
in COPD and asthma, and for comparison of the
diseases. Symptoms correlated with HRQL, whereas
between lung function and HRQL, the relationship was
weaker. HRQL seems to deteriorate
Elsevier Science and Technology, April 2002, Pages: 780
Chronic obstructive pulmonary disease (COPD), which encompasses both chronic bronchitis and emphysema, is one of the most common respiratory conditions of adults in the developed world. Asthma
Decision Resources, Inc., Oct 2011
Common respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) make up a large and varied pharmaceutical market sector. These diseases also impose a significant burden
Datamonitor, Aug 2011, Pages: 43
exposures and other air pollutants increase risk of COPD
Co-morbid conditions
Asthma and COPD can be confused in diagnosis
Pulmonary and respiratory infection are common exacerbations in COPD
TriMark Publications, May 2011, Pages: 158
, with special attention paid to therapeutic remedies for chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. Also addressed in this study are therapeutics for upper respiratory infections
